TABLE 1 MODERATE GROWTH SCENARIO OF ONCOLOGY/ CANCER DRUGS MARKET BY GEOGRAPHY, 2020 - 2025, ($MILLION)
TABLE 2 RAPID GROWTH SCENARIO OF ONCOLOGY/ CANCER DRUGS MARKET BY GEOGRAPHY, 2020 - 2025, ($MILLION)
TABLE 3 DIMINISHING GROWTH SCENARIO OF ONCOLOGY/ CANCER DRUGS MARKET BY GEOGRAPHY, 2020 - 2025, ($MILLION)
TABLE 4 APPLICABLE STANDARDS FOR THE UNITED STATES ANTICANCER DRUG DEVELOPMENT PROCESS
TABLE 5 INTERNATIONAL DISEASE CLASSIFICATION CODES AND DESCRIPTION OF CANCER DIAGNOSES
TABLE 6 CLINICAL LABORATORY FEE SCHEDULE (CLFS) REIMBURSEMENT CODES
TABLE 7 CLINICAL TRIALS FOR ONCOLOGY DRUGS
TABLE 8 WORLDWIDE ESTIMATED INCIDENCE AND PREVALENCE OF ALL CANCER TYPES, (EXCLUDING NON-MELANOMA SKIN CANCER) (2012)
TABLE 9 LIST OF BIOLOGICAL AND TARGETED DRUGS WITH THEIR REVENUE IN 2013 ($MILLION)
TABLE 10 LIST OF KEY PRODUCTS WITH THEIR PATENT EXPIRY DATES
TABLE 11 LIST OF COLLABORATIONS AND ACQUISITIONS FOR DEVELOPMENT OF ANTI-CANCER DRUGS
TABLE 12 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
TABLE 13 GLOBAL CHEMOTHERAPY DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
TABLE 14 GLOBAL TARGETED THERAPY DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
TABLE 15 CANCER IMMUNOTHERAPEUTICS AND THEIR CUMULATIVE PRICES
TABLE 16 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
TABLE 17 GLOBAL HORMONAL THERAPY DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
TABLE 18 GLOBAL OTHER THERAPY DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
TABLE 19 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY CANCER TYPES, 2013 - 2020 ($MILLION)
TABLE 20 INCIDENCE AND PREVALENCE OF BLOOD CANCER TYPES IN UNITED STATES
TABLE 21 USFDA APPROVED DRUGS FOR THE TREATMENT OF BLOOD CANCERS
TABLE 22 GLOBAL BLOOD CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
TABLE 23 WORLDWIDE INCIDENCE AND PREVALENCE OF BREAST CANCER (2012)
TABLE 24 GLOBAL BREAST CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
TABLE 25 WORLDWIDE INCIDENCE AND PREVALENCE OF GASTROINTESTINAL CANCER (2012)
TABLE 26 GLOBAL GASTROINTESTINAL CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
TABLE 27 WORLDWIDE INCIDENCE AND PREVALENCE OF PROSTATE CANCER (2012)
TABLE 28 DRUGS USED IN PROSTATE CANCER AND THEIR REVENUE (2013)
TABLE 29 GLOBAL PROSTATE CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
TABLE 30 WORLDWIDE INCIDENCE AND PREVALENCE OF LUNG CANCER (2012)
TABLE 31 LIST OF NEW THERAPEUTIC AGENTS FOR LUNG CANCER TREATMENT
TABLE 32 GLOBAL RESPIRATORY/LUNG CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
TABLE 33 GLOBAL SKIN CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
TABLE 34 WORLDWIDE INCIDENCE AND PREVALENCE OF CERVICAL CANCER (2012)
TABLE 35 GLOBAL OTHER CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
TABLE 36 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
TABLE 37 NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
TABLE 38 COSTS PER THERAPY OF THE COMMON CANCER DRUGS IN THE UNITED STATES:
TABLE 39 UNITED STATES ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
TABLE 40 CANADA ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
TABLE 41 MEXICO ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
TABLE 42 NEW ANTICANCER DRUGS APPROVED BY E MA 2013
TABLE 43 EUROPE ONCLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 - 2020 ($MILLION)
TABLE 44 GERMANY ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
TABLE 45 FRANCE ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
TABLE 46 UNITED KINGDOM ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
TABLE 47 OTHERS ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
TABLE 48 ASIA PACIFIC ONCLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 - 2020 ($MILLION)
TABLE 49 INDIA ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
TABLE 50 CHINA ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
TABLE 51 JAPAN ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
TABLE 52 AUSTRALIA ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
TABLE 53 OTHERS ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
TABLE 54 LAMEA ONCLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 - 2020 ($MILLION)
TABLE 55 GCC ONCLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 - 2020 ($MILLION)
TABLE 56 LATIN AMERICAN/ AFRICAN COUNTRIES AND THEIR PRICING POLICIES FOR CANCER THERAPIES
TABLE 57 OTHERS ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
TABLE 58 AMGEN INC. SNAPSHOT
TABLE 59 JOHNSON & JOHNSON SNAPSHOT
TABLE 60 JOHNSON AND JOHNSON OPERATING SEGEMENTS
TABLE 61 ROCHE DIAGNOSTICS SNAPSHOT
TABLE 62 ROCHE DIAGNOSTICS OPERATING SEGEMENTS
TABLE 63 GLAXOSMITHKLINE PLC SNAPSHOT
TABLE 64 GLAXOSMITHKLINE PLC OPERATING SEGEMENTS
TABLE 65 MERCK & COMPANY SNAPSHOT
TABLE 66 MERCK & CO. OPERATING SEGEMENTS
TABLE 67 NOVARTIS AG SNAPSHOT
TABLE 68 NOVARTIS AG OPERATING SEGEMENTS
TABLE 69 PFIZER SNAPSHOT
TABLE 70 PFIZER OPERATING SEGEMENTS
TABLE 71 SANOFI SNAPSHOTS
TABLE 72 SANOFI OPERATING SEGEMENTS
TABLE 73 ELI LILLY AND COMPANY SNAPSHOTS
TABLE 74 ELI LILLY AND COMPANY OPERATING SEGEMENTS
TABLE 75 CELGENE CORPORATION SNAPSHOTS
LIST OF FIGURE
FIG. 1 IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET IN MODERATE GROWTH SCENARIO
FIG. 2 IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET IN RAPID GROWTH SCENARIO
FIG. 3 IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET IN DIMINISHING GROWTH SCENARIO
FIG. 4 TOP FACTORS IMPACTING ONCOLOGY DRUGS MARKET (2014-2020)
FIG. 5 TOP INVESTMENT POCKETS OF ONCOLOGY/CANCER DRUGS MARKET (2013)
FIG. 6 TOP WINNING STRATEGIES FOR GLOBAL ONCOLOGY DRUG MARKET (2011-2013)
FIG. 7 TOP WINNING STRATEGIRS BY SUBTYPE
FIG. 8 PORTERS FIVE FORCES ANALYSIS OF ONCOLOGY DRUGS MARKET
FIG. 9 VALUE CHAIN ANALYSIS OF GLOBAL CANCER DRUGS MARKET
FIG. 10 PATENT ANALYSIS BY TYPE OF PATENTS (2011-2015)
FIG. 11 PATENT ANALYSIS BY GEOGRAPHY (2011-2015)
FIG. 12 MARKET SHARE ANALYSIS OF GLOBAL ONCOLOGY DRUG MARKET (2013)
FIG. 13 PERCENTAGE (%) OF ALL NEW CANCERS CASES DIAGNOSED IN 2012
FIG. 14 AMGEN INC. REVENUE BY GEOGRAPHY (2013)
FIG. 15 AMGEN INC. REVENUE BY PRODUCT PORTFOLIO (2013)
FIG. 16 SWOT ANALYSIS OF AMGEN INC.
FIG. 17 FINANCIAL REVENUE OF JOHNSON & JOHNSON BY GEOGRAPHY (2013)
FIG. 18 FINANCIAL REVENUE OF JOHNSON & JOHNSON BY BUSINESS UNITS (2013)
FIG. 19 SWOT ANALYSIS OF JOHNSON & JOHNSON
FIG. 20 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)
FIG. 21 ROCHE DIAGNOSTICS BY BUSINESS UNITS (2013)
FIG. 22 SWOT ANALYSIS OF ROCHE DIAGNOSTICS
FIG. 23 GLAXOSMITHKLINE PLC REVENUE BY GEOGRAPHY (2013)
FIG. 24 GLAXOSMITHKLINE PLC REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 25 SWOT ANALYSIS OF GLAXOSMITHKLINE PLC
FIG. 26 MERCK & CO. REVENUE BY GEOGRAPHY (2013)
FIG. 27 MERCK & CO. REVENUE BY BUSINESS UNITS (2013)
FIG. 28 SWOT ANALYSIS OF MERCK & COMPANY
FIG. 29 NOVARTIS AG REVENUE BY GEOGRAPHY (2013)
FIG. 30 NOVARTIS AG REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 31 SWOT ANALYSIS OF NOVARTIS AG
FIG. 32 PFIZER REVENUE BY GEOGRAPHY (2013)
FIG. 33 PFIZER REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 34 SWOT ANALYSIS OF PFIZER
FIG. 35 SANOFI REVENUE BY GEOGRAPHIES (2013)
FIG. 36 SANOFI REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 37 SWOT ANALYSIS OF SANOFI
FIG. 38 ELI LILLY AND COMPANY REVENUE BY GEOGRAPHIES (2013)
FIG. 39 ELI LILLY AND COMPANY REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 40 SWOT ANALYSIS OF ELI LILLY AND COMAPANY
FIG. 41 CELGENE CORPORATION REVENUE BY GEOGRAPHIES (2013)
FIG. 42 CELEGENE CORPORATION REVENUE BY PRODUCT SALES (2013)
FIG. 43 SWOT ANALYSIS OF CELGENE CORPORATION
